Payment overview · 2025
General Payments
$336.26
19 reported records · 8 companies
Healthcare provider profile · identity verified
Aric Ra-Sean Ray, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SIERRA VISTA, AZ · NPI 1245843465
Verified facts
What the public records show
CMS Open Payments records show Aric Ra-Sean Ray, FNP received $336.26 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.68 | 30.5% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.17 | 23.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.95 | 12.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.77 | 10.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.86 | 7.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.65 | 6.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.92 | 5.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.26 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $336.26 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $78.17 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.52 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.95 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| BYETTA Normalized: byetta |
Drug | AstraZeneca Pharmaceuticals LP | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 248 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 225 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 53 |
| Losartan Potassium | Losartan Potassium | 176 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 56 |
| Tramadol Hcl | Tramadol Hcl | 154 | 48 |
| Lisinopril | Lisinopril | 145 | 44 |
| Trazodone Hcl | Trazodone Hcl | 141 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 50 |
| Alprazolam | Alprazolam | 116 | 25 |
| Metformin Hcl | Metformin Hcl | 111 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 22 |
| Omeprazole | Omeprazole | 77 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 25 |
| Simvastatin | Simvastatin | 69 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 12 |
| Meloxicam | Meloxicam | 67 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 18 |
| Furosemide | Furosemide | 60 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 20 |
| Sertraline Hcl | Sertraline Hcl | 58 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 13 |
| Montelukast Sodium | Montelukast Sodium | 56 | 19 |
| Prednisone | Prednisone | 56 | 30 |
| Naproxen | Naproxen | 55 | 14 |
| Famotidine | Famotidine | 54 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 19 |
| Ibuprofen | Ibuprofen | 52 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 16 |
| Metformin Hcl Er | Metformin Hcl | 50 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 13 |
| Azithromycin | Azithromycin | 47 | 34 |
| Eliquis | Apixaban | 46 | 11 |
| Potassium Chloride | Potassium Chloride | 44 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | 12 |
| Fenofibrate | Fenofibrate | 36 | 14 |
| Carvedilol | Carvedilol | 35 | 13 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 23 |
| Ozempic | Semaglutide | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Glipizide | Glipizide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Estradiol | Estradiol | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $336.26 · 19 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BYETTA, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, Kerendia, MOUNJARO, VRAYLAR, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error